A genome-wide association study of carotid atherosclerosis in HIV-infected men

AIDS

Volumn 24, Issue 4, 2010, Pages 583-592

  Shrestha, Sadeep ^a   Irvin, Marguerite R ^a   Taylor, Kent D ^b   Wiener, Howard W ^a   Pajewski, Nicholas M ^a   Haritunians, Talin ^c   Delaney, Joseph A C ^d   Schambelan, Morris ^e   Polak, Joseph F ^f   Arnett, Donna K ^a   Chen, Yii Der Ida ^c   Grunfeld, Carl ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Genome wide association study; Highly active antiretroviral therapy; HIV; Intima media thickness

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RYANODINE RECEPTOR 3; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; B SCAN; CHROMOSOME 15; COMMON CAROTID ARTERY; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNAL CAROTID ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAROTID ARTERY DISEASES; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SEX DISTRIBUTION; UNITED STATES;

EID: 77649253929     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283353c9e     Document Type: Article

References (48)

1. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:e29-e35.
2. Martinez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis 2009; 22:28-34.
3. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118:198-210.
4. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008; 118:e20-e28.
5. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-1849.
6. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008; 196:720-726.
7. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
8. Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-148.
9. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
10. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM. Use ofhuman immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
11. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569-576.
12. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
13. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 (Suppl 1):S141-S148.
14. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8:283-289.
15. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SKJ. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
16. Hodis HN, Mack WJ, LaBreeL, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262-269.
17. Duggirala R, Gonzalez Villalpando C, O'Leary DH, Stern MP, Blangero J. Genetic basis of variation in carotid artery wall thickness. Stroke 1996; 27:833-837.
18. Fox CS, Polak JF, Chazaro I, Cupples A, Wolf PA, D'Agostino RA, O'Donnell CJ. Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke 2003; 34:397-401.
19. Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994; 236:567-573.
20. Mack WJ, LaBree L, Liu C, Selzer RH, H.N. H. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis 2000; 150:371-379.
21. Mercie P, Thiebaut R, Aurillac-Lavignolle V, Pellegrin JL, Yvor-ra-Vives MC, Cipriano C, et al. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005; 6:380-387.
22. Periard D, Cavassini M, Taffe P, Chevalley M, Senn L, Chapuis-Taillard C, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008; 46:761-767.
23. Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004; 110:2204-2209.
24. Coll B, Alonso-Villaverde C, Parra S, Montero M, Tous M, Joven J, Masana L. The stromal derived factor-1 mutated allele (SDF1-3A) is associated with a lower incidence of atherosclerosis in HIV-infected patients. AIDS 2005; 19:1877-1883.
25. Floris-MooreM,Fayad ZA, Berman JW, ManiV,Schoenbaum EE, Klein RS, et al. Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging. AIDS 2009; 23:941-949.
26. Coll B, Alonso-Villaverde C, Joven J. Monocyte chemoattrac-tant protein-1 and atherosclerosis: is there room for an additional biomarker? Clin Chim Acta 2007; 383:21-29.
27. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860-869.
28. Paschou P, Drineas P, Lewis J, Nievergelt CM, Nickerson DA, Smith JD, et al. Tracing sub-structure in the European American population with PCA-informative markers. PLoS Genet 2008; 4:e1000114.
29. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909.
30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575.
31. Gao X, Becker LC, Becker DM, Starmer JD, Province MA. Avoiding the high Bonferroni penalty in genome-wide association studies. Genet Epidemiol 2009. doi: 10.1002/gepi.20430.
32. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant S, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007; 17:1665-1674.
33. Bucan M, Abrahams BS, Wang K, Glessner JT, Herman EI, Sonnenblick LI, et al. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet 2009; 5:e1000536.
34. Jakobsson M, Scholz SW, Scheet P, Gibbs JR, VanLiere JM, Fung HC, et al. Genotype, haplotype and copy-number variation in worldwide human populations. Nature 2008; 451:998-1003.
35. Pevsner J. Analysis of genomic DNA with the UCSC genome browser. Methods Mol Biol 2009; 537:277-301.
36. Kent WJ, Hsu F, Karolchik D, Kuhn RM, Clawson H, Trumbower H, Haussler D. Exploring relationships and mining data with the UCSC Gene Sorter. Genome Res 2005; 15:737-741.
37. Sutko JL, Airey JA. Ryanodine receptor Ca2R release channels: does diversity in form equal diversity in function? Physiol Rev 1996; 76:1027-1071.
38. Leeb T, Brenig B. cDNA cloning and sequencing of the human ryanodine receptor type 3 (RYR3) reveals a novel alternative splice site in the RYR3 gene. FEBS Lett 1998; 423:367-370.
39. Kohler R, Brakemeier S, Kuhn M, Degenhardt C, Buhr H, Pries A, Hoyer J. Expression of ryanodine receptor type 3 and TRP channels in endothelial cells: comparison of in situ and cultured human endothelial cells. Cardiovasc Res 2001; 51:160-168.
40. PaladuguR,FuW,ConklinBS,LinPH,LumsdenAB,YaoQ,Chen C. Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38:549-555; discussion 555-1546
41. Norman JP, Perry SW, Reynolds HM, Kiebala M, De Mesy Bentley KL, Trejo M, et al. HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS One 2008; 3:e3731.
42. Yuan Z, Miyoshi T, Bao Y, Sheehan JP, Matsumoto AH, Shi W. Microarray analysis of gene expression in mouse aorta reveals role of the calcium signaling pathway in control of atherosclerosis susceptibility. Am J Physiol Heart Circ Physiol 2009; 296:H1336-1343.
43. Hejtmancik JF, Brink PA, Towbin J, Hill R, Brink L, Tapscott T, et al. Localization of gene for familial hypertrophic cardiomyo-pathy to chromosome 14q1 in a diverse US population. Circulation 1991; 83:1592-1597.
44. Emeson EE, Robertson AL Jr. T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis. Am J Pathol 1988; 130:369-376.
45. Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, Wick G. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 1993; 142:1927-1937.
46. Chambless LE, Zhong MM, Arnett D, Folsom AR, Riley WA, Heiss G. Variability in B-mode ultrasound measurements in the atherosclerosis risk in communities (ARIC) study. Ultrasound Med Biol 1996; 22:545-554. (Pubitemid 26230582)
47. Bots ML, Hoes AW, Hofman A, Witteman JC, Grobbee DE. Cross-sectionally assessed carotid intima-media thickness relates to long-term risk of stroke, coronary heart disease and death as estimated by available risk functions. J Intern Med 1999; 245:269-276.
48. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151:478-487.